Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 24;9(3):21.
doi: 10.3390/cancers9030021.

AR Signaling in Breast Cancer

Bilal Rahim  1 , Ruth O'Regan  2
Affiliations
Review

AR Signaling in Breast Cancer

Bilal Rahim et al. Cancers (Basel). .

Abstract

Androgen receptor (AR, a member of the steroid hormone receptor family) status has become increasingly important as both a prognostic marker and potential therapeutic target in breast cancer. AR is expressed in up to 90% of estrogen receptor (ER) positive breast cancer, and to a lesser degree, human epidermal growth factor 2 (HER2) amplified tumors. In the former, AR signaling has been correlated with a better prognosis given its inhibitory activity in estrogen dependent disease, though conversely has also been shown to increase resistance to anti-estrogen therapies such as tamoxifen. AR blockade can mitigate this resistance, and thus serves as a potential target in ER-positive breast cancer. In HER2 amplified breast cancer, studies are somewhat conflicting, though most show either no effect or are associated with poorer survival. Much of the available data on AR signaling is in triple-negative breast cancer (TNBC), which is an aggressive disease with inferior outcomes comparative to other breast cancer subtypes. At present, there are no approved targeted therapies in TNBC, making study of the AR signaling pathway compelling. Gene expression profiling studies have also identified a luminal androgen receptor (LAR) subtype that is dependent on AR signaling in TNBC. Regardless, there seems to be an association between AR expression and improved outcomes in TNBC. Despite lower pathologic complete response (pCR) rates with neoadjuvant therapy, patients with AR-expressing TNBC have been shown to have a better prognosis than those that are AR-negative. Clinical studies targeting AR have shown somewhat promising results. In this paper we review the literature on the biology of AR in breast cancer and its prognostic and predictive roles. We also present our thoughts on therapeutic strategies.

Keywords: AR signaling; AR/BET interplay; AR/PARP interplay; breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Abbreviated androgen and estrogen pathway. Arrows represent direction of enzymatic conversion.
Figure 2
Figure 2
Drug targets in AR signaling pathway.
See this image and copyright information in PMC

References

    1. Birrell S.N., Bentel J.M., Hickey T.E., Ricciardelli C., Weger M.A., Horsfall D.J., Tilley W.D. Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 1995;52:459–467. doi: 10.1016/0960-0760(95)00005-K. - DOI - PubMed
    1. Zhu X., Li H., Liu J.P., Funder J.W. Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. Mol. Cell. Endocrinol. 1999;152:199–206. doi: 10.1016/S0303-7207(99)00031-3. - DOI - PubMed
    1. Quigley C.A., De Bellis A., Marschke K.B., el-Awady M.K., Wilson E.M., French F.S. Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr. Rev. 1995;16:271–321. doi: 10.1210/edrv-16-3-271. - DOI - PubMed
    1. Foradori C.D., Weiser M.J., Handa R.J. Non-genomic actions of androgens. Front. Neuroendocrinol. 2008;29:169–181. doi: 10.1016/j.yfrne.2007.10.005. - DOI - PMC - PubMed
    1. Burger H.G. Androgen production in women. Fertil. Steril. 2002;77(Suppl. S4):S3–S5. doi: 10.1016/S0015-0282(02)02985-0. - DOI - PubMed